UK PM launches PICTF report
Published: 28-May-2001
The final report of the task force that has been investigating the competitiveness of the UK-based pharmaceutical industry was launched by the UK Prime Minister, Tony Blair. The report sets out action to be taken or in hand on a range of issues, including:
Industry and government agreed on the essential role that intellectual property rights and the TRIPs agreement play in the flow of innovative medicines;One of the most important outputs of the task force is the renewed industry/government partnership to work towards improving access to medicines in developing countries;Streamlining licensing procedures for essential research involving animals has been agreed, cutting red tape and improving animal welfare. This complements amendments to the Criminal Justice and Police Bill and Malicious Communications Act to tackle harassment and intimidation by animal rights;A more forward looking strategic dialogue about developments in healthcare and the market for medicines in the UK, for example discussions about how NICE operates, including the impact uptake of new medicines;Industry- and government-agreed positions on a range of medical issues under discussion in the EU. Blair said, 'It is a truly global industry. Companies have a real choice about where to invest… We have to ensure the UK remains an attractive place for new investment. We set up the task force to see what needed to be done and to take action to maintain and develop the UK's competitive edge.'
Tom McKillop, ceo of Astra Zeneca and the task force's joint chairman said, 'The UK government has demonstrated its willingness to work with us in ensuring the UK stays at the forefront of world pharmaceutical industry competitiveness. We have made significant progress on many issues.'
Copies of the report are available on the abpi website at www.abpi.org.uk.
